Results 61 to 70 of about 2,517 (166)

RVFV enrichment with NT53 incubation.

, 2013
A) RVFV was spiked into cell culture media (DMEM+++) at various concentrations from 1.0E+5 to 1.0E+1 pfu/ml. NT53 was added to 1 ml of media and captured according to standardize protocols. The pellet was washed 4 times with water, followed by processing
Fatah Kashanchi (45093), Benjamin Lepene (430923), Charles Bailey (61646), Aarthi Narayanan (166336), Chelsea Pinkham (173414), Nazly Shafagati (166328), Alan Baer (166320), Katherine Fite (430922), Kylene Kehn-Hall (45085)   +8 more
core   +1 more source

Structural basis for recognition of Rift Valley fever virus Gn protein by a human neutralizing monoclonal antibody with a kappa light chain.

PLoS Pathogens
Rift Valley fever virus (RVFV) poses a continued threat to human health and animal husbandry. Two neutralizing and protective human monoclonal antibodies (mAbs), RVFV-268 and RVFV-379, exhibit similar affinities and epitope footprints on the Gn ...
Guido C Paesen, Nathaniel S Chapman, Jonna B Westover, Cynthia M McMillen, Natalia A Kuzmina, Emmett A Dews, Luke Myers, Robert Stass, Joel M Montgomery, Alexander Bukreyev, Amy L Hartman, Brian B Gowen, James E Crowe, Thomas A Bowden   +13 more
doaj   +1 more source

Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale district in Southwestern Uganda, 2016.

PLoS Neglected Tropical Diseases, 2018
BackgroundRift Valley fever (RVF) is a zoonotic disease caused by Rift Valley fever virus (RVFV) found in Africa and the Middle East. Outbreaks can cause extensive morbidity and mortality in humans and livestock.
Luke Nyakarahuka, Annabelle de St Maurice, Lawrence Purpura, Elizabeth Ervin, Stephen Balinandi, Alex Tumusiime, Jackson Kyondo, Sophia Mulei, Patrick Tusiime, Julius Lutwama, John D Klena, Shelley Brown, Barbara Knust, Pierre E Rollin, Stuart T Nichol, Trevor R Shoemaker   +15 more
doaj   +1 more source

Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever virus

Frontiers in Cellular and Infection Microbiology, 2012
Humans infected with Rift Valley Fever virus (RVFV) generally recover after a febrile illness; however, a proportion of patients progress to a more severe clinical outcome such as hemorrhagic fever or meningoencephalitis.
Jacquelyn M. Bales, Diana S Powell, Laura M Bethel, Douglas S Reed, Douglas S Reed, Amy L Hartman, Amy L Hartman   +6 more
doaj   +1 more source

Development and Validation of Rapid Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification for Detection of Rift Valley Fever Virus

Advances in Virology, 2023
Rift Valley fever virus (RVFV) is a high-priority zoonotic pathogen with the ability to cause massive loss during its outbreak within a very short period of time.
Francis Wekesa, Mark Wamalwa, Richard Oduor, Yatinder Binepal, Leonard Ateya, Noah Okumu, Angela M’kwenda, Christopher Masaba, Eugine Mukhaye   +8 more
doaj   +1 more source

Toward Dual‐Function Nanoparticle Platforms for Arboviral Diagnostics and Vaccines: Advances, Challenges, and Future Prospects

Nano Select, Volume 7, Issue 2, February 2026.
This review explores nanoparticle (NP)‐based biosensors and nanovaccine platforms for arboviral infections, highlighting their design, performance, and translational potential. By comparing case studies across viruses, it identifies gold‐standard nanomaterials such as gold NPs (AuNPs), zinc oxide NPs (ZnONPs), molybdenum disulfide (MoS2) nanocomposites,
Peyman Halvaeikhanekahdani, Sajad Zandi, Qadeer Ahmad, Hadiseh Payravand   +3 more
wiley   +1 more source

RVFV-specific IgG antibodies detection in livestock (sheep and goats) and dogs using ELISA according to sampled route and village.

RVFV-specific IgG antibodies detection in livestock (sheep and goats) and dogs using ELISA according to sampled route and village.
Pierre Becquart (184034), Linda Bohou Kombila (18086830), Christophe Paupy (184029), Matthieu Fritz (4837230), Léadisaelle Hosanna Lenguiya (18086839), Marie-Marie Olive (606618), Gael Darren Maganga (18086845), Jessica Vanhomwegen (318167), Eric M. Leroy (15264367), Meriadeg Ar Gouilh (11288043), Illich Manfred Mombo (18086836), Larson Boundenga (749176), Telstar Ndong Mebaley (18086833), Nicolas Nesi (3564374), Camille Piro-Mégy (16316737), Nadine N’Dilimabaka (18086842), Déborah Garcia (6924839), Catherine Cêtre-Sossah (606622)   +17 more
core   +1 more source

MLN4924 inhibits RVFV infection.

, 2016
(A) IFA of RVFV N or G expression (green) in HeLa cells (cytoplasm in red) that were infected with ZH501 (MOI = 1, 24h) or MP-12 (MOI = 1, 24h) and were either treated with control DMSO (0.5%) or MLN4924 (1 μM) from 1h prior to start of infection to the ...
Krishna P. Kota (278100), Sina Bavari (154739), Cary Retterer (348525), Julie P. Tran (619684), Rajini Mudhasani (619683), Chris A. Whitehouse (30539)   +5 more
core   +1 more source

RVFV antigen in placentomes.

, 2020
Immunohistochemical (IHC) detection of RVFV antigen in cross sections of the placentomes at 4 dpi (experiment 2) and 6 dpi (experiment 1). At 4 dpi (A) only small foci of antigen positive cells are visible throughout the placentome while at 6 dpi (F ...
Judith Oymans (6061121), Jet Kant (475293), Paul J. Wichgers Schreur (8339304), Lucien van Keulen (299316), Jeroen Kortekaas (475294)   +4 more
core   +1 more source

Factors associated with Brucella, C.burnetii and RVFV positivity.

, 2022
Factors associated with Brucella, C.burnetii and RVFV positivity.
Isaac Lekolool (3417695), Lillian Wambua (6478289), Daniel Nthiwa (4615576), Collins Ouma (591083), John Gachohi (4386619), Athman Mwatondo (3074427), Kariuki Njenga (3074430), Richard Nyamota (10474511), Bernard Ronoh (13215329), Francis Gakuya (142647), Earl Middlebrook (13215332), Jeanne Fair (735592), Mathew Muturi (8488683), Bernard Bett (734348), James Akoko (5543228)   +14 more
core   +1 more source